SpringerLink
Log in

Characteristics and outcomes of COVID-19 in patients with plasma cell dyscrasias during the first Omicron wave in Bei**g since December 2022: a retrospective study at a National Clinical Research Center for Hematologic Disease

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The wave of coronavirus disease 2019 (COVID-19) with Omicron variant reached its first peak in Bei**g, China in December 2022. We delineated characteristics and factors associated with adverse outcome of patients with plasma cell dyscrasias (PCDs) and COVID-19 during the first month of the wave. A total of 104 patients with a median age of 65 years were included in the study, with multiple myeloma (74%, n=77) and primary Immunoglobulin light chain amyloidosis (16.3%, n=17) being the two most common disease. Overall, severe or critical COVID-19 was developed in 18 (17.3%) patients, with a total all-cause mortality rate of 4.8% (n=5). The vaccination coverage was 41% and 48.1%, before and during the upsurge of Omicron, respectively, calling for the improvement of vaccination in PCD patients. Multivariable analysis revealed that age was the only independent risk factors (OR=1.14, 95% CI: 1.06–1.26, p = 0.002) associated with the development of severe or critical disease. Among patients with severe or critical group, low levels of albumin (HR=18.29; 95% CI: 1.82–183.44, p = 0.013) and high levels of lactic dehydrogenase (LDH) (HR=0.08; 95% CI: 0.01–0.65, p = 0.018) were associated with longer time to negative conversion of COVID-19.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

The data that support the findings of this study are available from the corresponding author, ** Lu, upon reasonable request.

References

  1. Chinese Center For Disease Control And Prevention. National situation of SARS-CoV-2 infection 2023 [cited 2023]. Available from: https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202303/t20230304_264035.html. Accessed 29 Apr 2023

  2. Terpos E, Engelhardt M, Cook G et al (2020) Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia 34(8):2000–2011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ludwig H, Sonneveld P, Facon T et al (2021) COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol 8(12):e934–e946

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Langerbeins P, Hallek M (2022) COVID-19 in patients with hematologic malignancy. Blood 140(3):236–252

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pagano L, Salmanton-García J, Marchesi F et al (2021) COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol 14(1):168

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I et al (2022) Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy. Blood 139(9):1409–1412

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. World Health Organization. One year since the emergence of COVID-19 virus variant Omicron 2022. Available from: https://www.who.int/news-room/feature-stories/detail/one-year-since-the-emergence-of-omicron. Accessed 25 Nov 2022

  8. National Medical Products Administration 2021 Available from: https://www.nmpa.gov.cn/zhuanti/yqyjzxd/yqyjxd/20210206154636109.html. Accessed 19 Apr 2023

  9. National Medical Products Administration 2021 Available from: https://www.nmpa.gov.cn/directory/web/nmpa/yaowen/ypjgyw/20210225184306142.html. Accessed 19 Apr 2023

  10. National Comprehensive Cancer Network. Prevention and treatment of cancer-related infections. NCCN Guidelines Version 3.2022. 2022

  11. Liu Y, Gao W, Guo W et al (2020) Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-19. J Thromb Thrombolysis 50(4):825–832

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. World Health Organization. Statement on the fourteenth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic 2023. Available from: https://www.who.int/news/item/30-01-2023-statement-on-the-fourteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(COVID-19)-pandemic

  13. World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic 2023. Available from: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic

  14. Ho M, Zanwar S, Buadi FK et al (2023 Jan) Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol 98(1):49–55

    Article  CAS  PubMed  Google Scholar 

  15. Cook G, John Ashcroft A, Pratt G et al (2020) Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol 190(2):e83–e86

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Wang B, Van Oekelen O, Mouhieddine TH et al (2020) A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol 13(1):94

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Martínez-López J, Mateos M-V, Encinas C et al (2020) Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality. Blood. Cancer J 10(10):103

    Google Scholar 

  18. Chari A, Samur MK, Martinez-Lopez J et al (2020) Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood 136(26):3033–3040

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Engelhardt M, Shoumariyeh K, Rösner A et al (2020) Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. Haematologica 105(12):2872–2878

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bilinski A, Thompson K, Emanuel E (2023) COVID-19 and excess all-cause mortality in the US and 20 comparison countries, June 2021-March 2022. JAMA 329(1):92–94

    Article  PubMed  Google Scholar 

  21. Cheung PH, Chan CP, ** DY (2022) Lessons learned from the fifth wave of COVID-19 in Hong Kong in early 2022. Emerg Microbes Infect 11(1):1072–1078

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Terpos E, Musto P, Engelhardt M et al (2023) Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). Leukemia 37(6):1175–1185

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Terpos E, Branagan AR, García-Sanz R et al (2023) Report of consensus panel 5 from the 11th international workshop on Waldenstrom’s macroglobulinemia on COVID-19 prophylaxis and management. Semin Hematol 60(2):107–112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ashruf OS, Orozco Z, Kaelber DC (2023) Risk and severity of COVID-19 infection in monoclonal gammopathy of undetermined significance: a 3-year propensity matched cohort study. Clin Lymph Myeloma Leukemia. https://doi.org/10.1016/j.clml.2023.04.010

  25. Liatsou E, Ntanasis-Stathopoulos I, Lykos S et al (2023) Adult patients with cancer have impaired humoral responses to complete and booster COVID-19 vaccination, especially those with hematologic cancer on active treatment: a systematic review and meta-analysis. Cancers 15(8):2266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Aleman A, Van Oekelen O, Upadhyaya B et al (2022) Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients. Cancer Cell. 40(5):441–443

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Hoornaert E, Dachy F, Hansenne A et al (2022) COVID-19: impact of vaccination in myeloma patients. Ann Hematol 101(7):1607–1608

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Rosati M, Terpos E, Bear J, et al. Low spike antibody levels and impaired BA.4/5 neutralization in patients with multiple myeloma or Waldenstrom’s macroglobulinemia after BNT162b2 booster vaccination. Cancers 2022;14(23): 5816

  29. Liu Y, Yan LM, Wan L et al (2020 Jun) Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 20(6):656–657

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Viana-Llamas MC, Arroyo-Espliguero R, Silva-Obregón JA et al (2021) Hypoalbuminemia on admission in COVID-19 infection: an early predictor of mortality and adverse events. A retrospective observational study. Med Clin (Barc) 156(9):428–436

    Article  CAS  PubMed  Google Scholar 

  31. Xu Y, Yang H, Wang J et al (2021) Serum albumin levels are a predictor of COVID-19 patient prognosis: evidence from a single cohort in Chongqing, China. Int J Gen Med 14:2785–2797

    Article  PubMed  PubMed Central  Google Scholar 

  32. Turcato G, Zaboli A, Kostic I et al (2022) Severity of SARS-CoV-2 infection and albumin levels recorded at the first emergency department evaluation: a multicentre retrospective observational study. Emerg Med J 39(1):63–69

    Article  PubMed  Google Scholar 

  33. Medina-Hernández EO, Pérez-Navarro LM, Hernández-Ruiz J et al (2022) Changes in lactate dehydrogenase on admission throughout the COVID-19 pandemic and possible impacts on prognostic capability. Biomark Med 16(14):1019–1028

    Article  PubMed  Google Scholar 

  34. Henry BM, Aggarwal G, Wong J et al (2020) Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Am J Emerg Med 38(9):1722–1726

    Article  PubMed  PubMed Central  Google Scholar 

  35. Ho M, Zanwar S, Buadi FK et al (2022) Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance. Blood 140(18):1997–2000

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I et al (2021) The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J 11(8):138

    Article  PubMed  PubMed Central  Google Scholar 

  37. Ludwig H, San-Miguel J, Munshi N et al (2021) Covid-19 vaccination in patients with multiple myeloma: focus on immune response. Am J Hematol 96(8):896–900

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was funded by Capital’s Funds for Health Improvement and Research 2020-2-4082.

Author information

Author notes

  1. The authors Qing He and Xuelin Dou contributed equally to this work.

Authors and Affiliations

  1. National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People’s Hospital, Bei**g, 100044, China

    Qing He, Xuelin Dou, Yang Liu, Lei Wen, Fengrong Wang, Nan Peng, Lizhong Gong, Yue Li, Yao Lu, **aohui Zhang, **aojun Huang & ** Lu

  2. Department of Hematology, Fu **ng Hospital, Capital Medical University, Bei**g, 100038, China

    Liru Wang

  3. Collaborative Innovation Center of Hematology, Soochow University, Suzhou, 215006, China

    ** Lu

Authors
  1. Qing He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xuelin Dou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lei Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fengrong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nan Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lizhong Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yue Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yao Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Liru Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. **aohui Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. **aojun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. ** Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to ** Lu.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

ESM 1

Supplemental Table 1. Characteristics of MM patients. Supplemental Table 2. Characteristics of AL patients. Supplemental Table 3. Symptoms and vaccination status. Supplemental Table 4. COVID-19 related outcomes. Supplemental Table 5. Vaccination status before the upsurge of Omicron (DOCX 20 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

He, Q., Dou, X., Liu, Y. et al. Characteristics and outcomes of COVID-19 in patients with plasma cell dyscrasias during the first Omicron wave in Bei**g since December 2022: a retrospective study at a National Clinical Research Center for Hematologic Disease. Ann Hematol 102, 2857–2864 (2023). https://doi.org/10.1007/s00277-023-05350-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-023-05350-y

Keywords

Search

Navigation